Predictive Oncology Inc. (NASDAQ:POAI) shares, dropped in value on Wednesday, Jan 13, with the stock price down by -1.85% to the previous day’s close as weak demand from buyers trailed the stock to $0.9.
Actively observing the price movement in the last trading, the stock closed the session at $0.92, falling within a range of $0.8700 and $0.9800. The value of beta (5-year monthly) was 1.78 whereas the PE ratio was 0 over 12-month period. Referring to stock’s 52-week performance, its high was $5.3, and the low was $0.63. On the whole, POAI has fluctuated by 22.5% over the past month.
We see that POAI’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Sell.
A comparison of Predictive Oncology Inc. (POAI) with its peers suggests the former has fared considerably weaker in the market. POAI showed an intraday change of -1.85% in last session, and over the past year, it dropped by -67.36%. In comparison, Cerner Corp (CERN) has moved higher at +2.18% on the day and was up +8.68% over the past 12 months. On the other hand, the price of 10X Genomics Inc (TXG) has risen 4.67% on the day. The stock, however, is off 107.45% from where it was a year ago. Additionally, there is a decline of -185% for Invitae Corp (NVTA) in last trading while the stock has seen an overall depriciation of -67.36% over the past year. The PE ratio stands at 0 for Predictive Oncology Inc., compared to 31.54 for Cerner Corp, and 0 for 10X Genomics Inc. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 0.23%. Meanwhile, the Dow Jones Industrial weakened by -0.03%.
Data on historical trading for Predictive Oncology Inc. (NASDAQ:POAI) indicates that the trading volumes over the past 10 days have averaged 3.94 Million and over the past 3 months, they’ve averaged 1.13 Million. According to company’s latest data on outstanding shares, there are 17.68 Million shares outstanding.
Nearly 10.36% of Predictive Oncology Inc.’s shares belong to company insiders and institutional investors own 2.17% of the company’s shares, according to Thomson Reuters’ data. The data on short interest also indicates that stock shorts accounted for 428.23 Million shares as on December 30, 2020, resulting in a short ratio of 0.29. According to the data, the short interest in Predictive Oncology Inc. (POAI) stood at 2.42% of shares outstanding as of December 30, 2020; the number of short shares registered in November reached 315.95 Million. The stock has risen by +23.27% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the POAI stock heading into the next quarter.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.